Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 15, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 975,000 ordinary shares of 25 pence each.
- Purchase Price: 1,514.83 pence per share.
- Treasury Shares Held: 162,314,678 shares (post-transaction).
- Shares in Issue: 5,818,874,713 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 975,000 shares on May 15, 2006, which are now held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase by multiplying 975,000 shares by 1,514.83 pence.
- Confirm the updated total share count (5,818,874,713 issued) against subsequent filings.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the authorized buyback program.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for those metrics.